来源:[1] 特朗普、礼来、诺和诺德公布肥胖药物降价协议 (https://www.cnbc.com/2025/11/06/trump-eli-lil ...)[2] 礼来公布亮眼第三季度业绩:长期上涨空间巨大 | Investing.com (https://www.investing.com/analysis/eli-lilly- ...)[3] 肥胖药物市场竞争白热化 - DCAT 价值链洞察 (https://www.dcatvci.com/14187-novo-nordisk-pf ...)